Please assess the completion status of the following clinical trial:

Trial Title: Topical Cetirizine in Androgenetic Alopecia in Females

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE2/PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Females with androgenetic alopecia of age 20-50 years.~2. Patients experiencing active hair loss within the last 12 months.~3. Sinclair scale 2, 3 and 4.~4. Patients willing to continue their current regimen of vitamins and nutritional supplements and not start any new vitamins or nutritional supplements for the duration of the study.~5. Patients willing to use a mild non-medicated shampoo and conditioner for the duration of the study.~6. Patients who did not receive topical or systemic treatment for androgenetic alopecia or prostaglandins in the last 6 months.~Exclusion Criteria:~* 1. Patients with a chronic dermatological condition (eczema, psoriasis, infection, etc) of the scalp other than FPHL.~  2. Subjects who had hair transplants, scalp reduction, current hair weave or tattooing in the target area, which makes it difficult to perform hair count assessment.~  3. Subjects who received radiation therapy to the scalp, or has had chemotherapy in the past year.~  4. Subjects who have a known underlying medical problem that could influence hair growth such as HIV infection, connective tissue disease, a thyroid condition, inflammatory bowel disease or other medical conditions, at the discretion of the investigator.~  5. Subjects with clinical diagnosis of alopecia areata or other non-AGA forms of alopecia.~  6. Pregnant or lactating females or planning to become pregnant for the duration of the study.~  7. Patients with severe cardiovascular disease, uncontrolled or untreated hypertension, arrythmia or clinically relevant hypotension.~  8. Subjects with hair loss for greater than 5 years, as medical therapy is unlikely to have much effect at restoring hair follicles inactive for that long of a period.~  9. The subject has known hypersensitivity or previous allergic reaction to any of the active or inactive components of the test articles.~  10. Patients using any medications that potentially cause drug-induced hair loss (e.g., depotestosterone, haloperidol, methotrexate, methylprednisolone, prednisone, testosterone, divalproex sodium) within the last 3 months.

- Gender: FEMALE
- Minimum Age: 20 Years
- Maximum Age: 50 Years
- Healthy Volunteers: f

Study Arms:
- Study group (Type: EXPERIMENTAL): (33) patients will apply topical minoxidil (5%) once daily and topical cetirizine (1%) once daily on their scalp for 6 months.
- Control group (Type: ACTIVE_COMPARATOR): (33) patients will apply topical minoxidil (5%) once daily and placebo once daily on their scalp for 6 months.

Based on this trial design, predict the completion outcome and termination type (if applicable).